A cell engineering strategy to enhance the safety of stem cell therapies

The long-term risk of malignancy associated with stem cell therapies is a significant concern in the clinical application of this exciting technology. We report a cancer-selective strategy to enhance the safety of stem cell therapies. Briefly, using a cell engineering approach, we show that aggressive cancers derived from human or murine induced pluripotent stem cells (iPSCs) and embryonic stem cells (ESCs) are strikingly sensitive to temporary MYC blockade. On the other hand, differentiated tissues derived from human or mouse iPSCs can readily tolerate temporary MYC inactivation. In cancer cells, endogenous MYC is required to maintain the metabolic and epigenetic functions of the embryonic and cancer-specific pyruvate kinase M2 isoform (PKM2). In summary, our results implicate PKM2 in cancer's increased MYC dependence and indicate dominant MYC inhibition as a cancer-selective fail-safe for stem cell therapies.


Published in:
Cell reports, 8, 6, 1677-85
Year:
2014
Publisher:
Elsevier
ISSN:
2211-1247
Laboratories:




 Record created 2014-10-20, last modified 2018-01-28

External link:
Download fulltext
Publisher's version
Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)